Clinical Trial Update: A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 crossover bioequivalence study comparing Olaparib 150 mg tablets from Lek Pharmaceuticals with Lynparza 150 mg tablets in BRCA-mutated ovarian cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer

Drugs mentioned

• Lynparza (Olaparib) Tablets 150 mg (Olaparib)
• Olaparib Tablets 150 mg (Lek Pharmaceuticals d.d.) (Olaparib)

Snippet

Sponsor: Sandoz | Conditions: Ovarian Cancer, Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2024-10-03